Analysis

Kalvista Pharmaceuticals, Inc. (KALV) Stock Analysis

Kalvista Pharmaceuticals, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to KALV.

websiteKALV/analysis/KALV

Kalvista Pharmaceuticals, Inc.

Kalvista Pharmaceuticals, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to KALV.

Stock profile

Ticker

KALV

Asset type

Stock

Market cap

$1.43B

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

USD

Ticker listings

Kalvista Pharmaceuticals, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • KALV primary listing
  • 4XC1
  • A2DG49

Latest Kalvista Pharmaceuticals, Inc. news

Chiesi Group Completes Acquisition of KalVista Pharmaceuticals

PARMA, Italy & FRAMINGHAM, Mass., June 11, 2026--Chiesi Group ("Chiesi"), an international research-focused biopharmaceutical group and certified B Corp, today announced the com...

KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary An...

KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary

Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio

PARMA, Italy & FRAMINGHAM, Mass., April 29, 2026--Chiesi Group ("Chiesi"), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceu...

KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in

KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-...

Interim data show sebetralstat enables early, effective treatment of hereditary angioedema (HAE) attacks in children with favorable safety and tolerability

Research sections

Valuation

Review valuation context for Kalvista Pharmaceuticals, Inc..

Future growth

Review future growth context for Kalvista Pharmaceuticals, Inc..

Past performance

Review past performance context for Kalvista Pharmaceuticals, Inc..

Financial health

Review financial health context for Kalvista Pharmaceuticals, Inc..

Dividend

Review dividend context for Kalvista Pharmaceuticals, Inc..

Management

Review management context for Kalvista Pharmaceuticals, Inc..

Ownership

Review ownership context for Kalvista Pharmaceuticals, Inc..

Other information

Review other information context for Kalvista Pharmaceuticals, Inc..

Community

Review community context for Kalvista Pharmaceuticals, Inc..